News | January 26, 2022
Cipla’s Q3FY22 PAT at Rs 729 cr.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
Al-Futtaim will utilize TytoCare's TytoPro system in outpatient clinics around Dubai, providing patients with enhanced care and better access to specialists
The country is sixth among the most affected countries by active cases
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
This is the company’s first partnership arrangement in China
Subscribe To Our Newsletter & Stay Updated
